Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
Is this big pharma stock still a buy for investors who aren't billionaires?
Stanley Druckenmiller and Ken Griffin, both billionaire investors, recently increased their stakes in Eli Lilly, a pharmaceutical company. Citadel Advisors, managed by Griffin, boosted its position in Lilly by 291% in the second quarter of 2026, making Lilly the eighth-largest holding in the fund, valued at around $1.1 billion. Druckenmiller's Duquesne Family Office made a smaller investment in Lilly, buying 12,380 shares in Q2.
Both investors seem to agree on Lilly's strong position in the diabetes and obesity drug markets, with successful products like Mounjaro and Zepbound driving the company's growth. While Lilly's stock has risen by a significant percentage year-to-date, it has also seen a temporary dip. Investors should not solely follow the lead of these billionaires, as market conditions may have changed since their purchases.
Nevertheless, Eli Lilly appears to be a promising investment due to its strong revenue and earnings growth, upcoming new drugs, and acquisition strategy.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
